February 07, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Breast Cancer

» Advanced search

Latest Issue

Volume 22 Issue 2

» Browse recent issues

Volume 22 Issue 2

Leading ArticlesClick to expand
- Alcohol Consumption and Breast Cancer
  
  in CML Breast Cancer (Volume 22 Issue 2 / Leading Articles)
  
  Amy W Wong¹, Jina Hong², and Nomeli P Nuñez^1,2
  
  ¹Institute of Cell and Molecular Biology, ²Department of Nutritional Sciences, University of Texas, Austin, TX, USA
  
  Breast cancer is the second leading cause of cancer-related death among women in the US after lung cancer [1]. In 2009, approximately 40 000 women died from breast cancer and approximately 192 000 new cases were diagnosed in US women [2].
  » Read more
Clinical ReviewsClick to expand
- Biology – Disease 
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Biology – Emerging Therapies
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Risk – Primary Disease
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Risk – Recurrence or Contralateral Disease
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Imaging
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Prognostic Factors and Staging
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Treatment – Radiotherapy
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Treatment – Complications
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more
- Treatment – Metastatic and Advanced Disease
  
  in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)
  
  » Read more

« Back

READER POLL

What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?

Continuation of trastuzumab with an alternative cytotoxic agent
An alternative cytotoxic agent alone
A HER1/2 tyrosine kinase inhibitor with or without cytotoxic chemotherapy
Continuation of trastuzumab with a HER1/2 tyrosine inhibitor
Other

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

February 07, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

Latest Issue

Volume 22 Issue 2

Leading Articles

Amy W Wong1, Jina Hong2, and Nomeli P Nuñez1,2

Clinical Reviews

Volume 22 Issue 2

Leading ArticlesClick to expand

in CML Breast Cancer (Volume 22 Issue 2 / Leading Articles)

Amy W Wong1, Jina Hong2, and Nomeli P Nuñez1,2

Clinical ReviewsClick to expand

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

in CML Breast Cancer (Volume 22 Issue 2 / Clinical Reviews)

READER POLL

Post Page On

SUBMIT AN ARTICLE

February 07, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

Amy W Wong¹, Jina Hong², and Nomeli P Nuñez^1,2

Amy W Wong¹, Jina Hong², and Nomeli P Nuñez^1,2